Interference between D30N and L90M in selection and development of protease inhibitor-resistant human immunodeficiency virus type 1.
We studied the evolutionary relationships between the two protease inhibitor (PI) resistance mutations, D30N and L90M, of human immunodeficiency virus type 1 (HIV-1). The former is highly specific for nelfinavir resistance, while the latter is associated with resistance to several PIs, including nelfinavir. Among patients with nelfinavir treatment failure, we found that D30N acquisition was strongly suppressed when L90M preexisted. Thus, D30N/L90M double mutations not only were detected in a very limited number of patients but also accounted for a minor fraction within each patient. In the disease course, the D30N and L90M clones readily evolved independently of each other, and later the D30N/L90M double mutants emerged. The double mutants appeared to originate from the D30N lineage but not from the L90M lineage, or were strongly associated with the former. However, their evolutionary pathways appeared to be highly complex and to still have something in common, as they always contained several additional polymorphisms, including L63P and N88D, as common signatures. These results suggest that D30N and L90M are mutually exclusive during the evolutionary process. Supporting this notion, the D30N/L90M mutation was also quite rare in a large clinical database. Recombinant viruses with the relevant mutations were generated and compared for the ability to process p55gag and p160pol precursor proteins as well as for their infectivity. L90M caused little impairment of the cleavage activities, but D30N was detrimental, although significant residual activity was observed. In contrast, D30N/L90M demonstrated severe impairment. Thus, the concept of mutual antagonism of the two mutations was substantiated biochemically and functionally.
Sugiura
Wataru
W
AIDS Research Center, National Institute of Infectious Diseases, Musashimurayama, Tokyo 2080011, Japan. wsuguira@nih.go.jp
Matsuda
Zene
Z
Yokomaku
Yoshiyuki
Y
Hertogs
Kurt
K
Larder
Brendan
B
Oishi
Tsuyoshi
T
Okano
Aiko
A
Shiino
Teiichirou
T
Tatsumi
Masashi
M
Matsuda
Masakazu
M
Abumi
Hanae
H
Takata
Noboru
N
Shirahata
Satoshi
S
Yamada
Kaneo
K
Yoshikura
Hiroshi
H
Nagai
Yoshiyuki
Y
D003001:Cloning, Molecular; D004352:Drug Resistance, Microbial; D015683:Gene Products, gag / Q000032:analysis / Q000235:genetics; D015658:HIV Infections / Q000821:virology; D016333:HIV Protease / Q000235:genetics*; D017320:HIV Protease Inhibitors / Q000494:pharmacology*; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics / Q000472:pathogenicity; D007700:Kinetics; D009154:Mutation / Q000235:genetics; D010802:Phylogeny; D011498:Protein Precursors / Q000032:analysis / Q000235:genetics; D012367:RNA, Viral / Q000032:analysis / Q000096:biosynthesis / Q000235:genetics; D014779:Virus Replication / Q000187:drug effects
D015683:Gene Products, gag; D017320:HIV Protease Inhibitors; D011498:Protein Precursors; D012367:RNA, Viral; C059767:p55 gag precursor protein, Human immunodeficiency virus 1; D016333:HIV Protease